Estramustine: all 48 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate CancerTerminatedNCT02560051Phase 2Results posted
• Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate CancerTerminatedNCT02494713Phase 2Results posted
• S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate CancerCompletedNCT00028769Phase 2Results posted
• Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate CancerTerminatedNCT00024167Phase 3Results posted
• Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate CancerCompletedNCT00016913Phase 2Results posted
• Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00004054Phase 3Results posted
• Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.CompletedNCT02866955Phase 2
• Efficacy and Safety of Estracyt® in Metastatic Breast CancerWithdrawnNCT02853071Phase 2
• Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate CancerTerminatedNCT00705822Phase 3
• Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic CancerCompletedNCT00541281Phase 2
• A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate CancerStatus unknownNCT00218205Phase 2
• Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate CancerCompletedNCT00193271Phase 2
• Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate CarcinomaCompletedNCT00193193Phase 2
• Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.CompletedNCT00183924Phase 2
• Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00176527Phase 2
• Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local TreatmentCompletedNCT00165399Phase 2
• Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate CancerCompletedNCT00151086Phase 1/2
• Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateCompletedNCT00151073Phase 2
• Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the ProstateCompletedNCT00151060Phase 2
• Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate CancerTerminatedNCT00132756Phase 1/2
• Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate CancerWithdrawnNCT00084565Phase 2
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the ProstateCompletedNCT00083005Phase 2
• Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of RelapseCompletedNCT00055731Phase 3
• Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00052845Phase 2
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone TherapyCompletedNCT00046826Phase 2
• Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate CarcinomaCompletedNCT00038246Phase 1/2
• Intravenous Estramustine With Taxol in Hormone Refractory Prostate AdenocarcinomaCompletedNCT00038168Phase 1/2
• Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00030654Phase 3
• Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate CancerCompletedNCT00027859Phase 3
• Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate CancerCompletedNCT00025194Phase 1/2
• Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00021372Phase 2
• Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate CancerCompletedNCT00016107Phase 2
• Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate CancerCompletedNCT00014352Phase 2
• Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005847Phase 2
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005810Phase 2
• Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005627Phase 1
• Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005048Phase 1
• Combination Chemotherapy in Treating Patients With Advanced CancerCompletedNCT00004105Phase 1/2
• S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00004001Phase 3
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerStatus unknownNCT00003717Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Prostate CancerStatus unknownNCT00003633Phase 1
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerCompletedNCT00003614Phase 2
• Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney CancerCompletedNCT00003584Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003394Phase 1/2
• Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast CancerStatus unknownNCT00003066Phase 2
• Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate CancerCompletedNCT00002855Phase 3
• Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerStatus unknownNCT00002775Phase 1/2
• Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate CancerCompletedNCT00002721Phase 1

← Estramustine overview